AR018139A1 - Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento. - Google Patents
Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento.Info
- Publication number
- AR018139A1 AR018139A1 ARP990100880A ARP990100880A AR018139A1 AR 018139 A1 AR018139 A1 AR 018139A1 AR P990100880 A ARP990100880 A AR P990100880A AR P990100880 A ARP990100880 A AR P990100880A AR 018139 A1 AR018139 A1 AR 018139A1
- Authority
- AR
- Argentina
- Prior art keywords
- hidroxi
- halo
- manufacture
- same
- glici
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 title 1
- 235000004279 alanine Nutrition 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3427098A | 1998-03-04 | 1998-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR018139A1 true AR018139A1 (es) | 2001-10-31 |
Family
ID=21875345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990100880A AR018139A1 (es) | 1998-03-04 | 1999-03-02 | Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento. |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1060164A1 (is) |
| JP (1) | JP2002505323A (is) |
| KR (1) | KR20010041584A (is) |
| CN (1) | CN1214011C (is) |
| AP (1) | AP1244A (is) |
| AR (1) | AR018139A1 (is) |
| AU (1) | AU753230B2 (is) |
| BG (1) | BG104740A (is) |
| BR (1) | BR9908470A (is) |
| CA (1) | CA2322207A1 (is) |
| EA (1) | EA200000804A1 (is) |
| EE (1) | EE200000506A (is) |
| GE (1) | GEP20033118B (is) |
| HR (1) | HRP20000574A2 (is) |
| HU (1) | HUP0100865A3 (is) |
| ID (1) | ID25591A (is) |
| IL (1) | IL137653A0 (is) |
| IS (1) | IS5582A (is) |
| MY (1) | MY123908A (is) |
| NO (1) | NO315703B1 (is) |
| NZ (1) | NZ506598A (is) |
| OA (1) | OA11530A (is) |
| PL (1) | PL342726A1 (is) |
| SK (1) | SK13002000A3 (is) |
| TR (1) | TR200002542T2 (is) |
| UA (1) | UA71906C2 (is) |
| WO (1) | WO1999044994A1 (is) |
| YU (1) | YU52000A (is) |
| ZA (1) | ZA994406B (is) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
| JP2003531141A (ja) | 2000-04-17 | 2003-10-21 | セルテック アール アンド ディ リミテッド | エナミン誘導体 |
| US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
| US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
| US6921767B2 (en) * | 2000-06-15 | 2005-07-26 | Pharmacia Corporation | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives |
| JP2004505110A (ja) | 2000-08-02 | 2004-02-19 | セルテック アール アンド ディ リミテッド | ３位置換イソキノリン−１−イル誘導体 |
| AU2003299600A1 (en) * | 2002-12-20 | 2004-07-29 | Pharmacia Corpration | The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| BRPI0611814A2 (pt) * | 2005-06-10 | 2008-12-09 | Bipar Sciences Inc | moduladores parp e tratamento de cÂnceres |
| CN101687040A (zh) | 2007-03-01 | 2010-03-31 | 马林克罗特公司 | 整合光活性的小分子及其用途 |
| JP4792124B1 (ja) * | 2010-11-15 | 2011-10-12 | エフイートレード株式会社 | 車両用保護フィルムの型取り方法、及び、車両用保護フィルムの製造方法 |
| US8716226B2 (en) | 2012-07-18 | 2014-05-06 | Saint Louis University | 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists |
| IN2015DN00099A (is) | 2012-07-18 | 2015-05-29 | Univ Saint Louis | |
| WO2015181676A1 (en) | 2014-05-30 | 2015-12-03 | Pfizer Inc. | Carbonitrile derivatives as selective androgen receptor modulators |
| WO2015187774A1 (en) * | 2014-06-04 | 2015-12-10 | Monsanto Technology Llc | 3,6-dichlorosalicylic acid compounds and related synthetic processes |
| CN108779077A (zh) | 2015-12-30 | 2018-11-09 | 圣路易斯大学 | 作为pan整合素拮抗剂的间位氮杂环氨基苯甲酸衍生物 |
| CA3182964A1 (en) | 2020-05-14 | 2021-11-18 | Ube Corporation | 1,4,5,6-tetrahydropyrimidin-2-amine derivative |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
| JPWO2023085396A1 (is) | 2021-11-12 | 2023-05-19 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ293323B6 (cs) * | 1995-08-30 | 2004-04-14 | G. D. Searle & Co. | Meta-guanidinové, močovinové, thiomočovinové nebo azacyklické deriváty aminobenzoové kyseliny jako antagonisty integrinů |
-
1999
- 1999-02-11 ZA ZA9904406A patent/ZA994406B/xx unknown
- 1999-02-22 YU YU52000A patent/YU52000A/sh unknown
- 1999-02-22 TR TR2000/02542T patent/TR200002542T2/xx unknown
- 1999-02-22 EP EP99937927A patent/EP1060164A1/en active Pending
- 1999-02-22 GE GEAP19995537A patent/GEP20033118B/en unknown
- 1999-02-22 BR BR9908470-8A patent/BR9908470A/pt not_active Application Discontinuation
- 1999-02-22 HU HU0100865A patent/HUP0100865A3/hu unknown
- 1999-02-22 JP JP2000534538A patent/JP2002505323A/ja active Pending
- 1999-02-22 AU AU32947/99A patent/AU753230B2/en not_active Ceased
- 1999-02-22 SK SK1300-2000A patent/SK13002000A3/sk unknown
- 1999-02-22 CA CA002322207A patent/CA2322207A1/en not_active Abandoned
- 1999-02-22 EA EA200000804A patent/EA200000804A1/ru unknown
- 1999-02-22 OA OA1200000238A patent/OA11530A/en unknown
- 1999-02-22 EE EEP200000506A patent/EE200000506A/xx unknown
- 1999-02-22 IL IL13765399A patent/IL137653A0/xx unknown
- 1999-02-22 PL PL99342726A patent/PL342726A1/xx unknown
- 1999-02-22 UA UA2000095148A patent/UA71906C2/uk unknown
- 1999-02-22 CN CNB998035815A patent/CN1214011C/zh not_active Expired - Fee Related
- 1999-02-22 AP APAP/P/2000/001893A patent/AP1244A/en active
- 1999-02-22 NZ NZ506598A patent/NZ506598A/en unknown
- 1999-02-22 WO PCT/US1999/003281 patent/WO1999044994A1/en not_active Ceased
- 1999-02-22 KR KR1020007009774A patent/KR20010041584A/ko not_active Ceased
- 1999-02-22 HR HR20000574A patent/HRP20000574A2/hr not_active Application Discontinuation
- 1999-02-22 ID IDW20001695A patent/ID25591A/id unknown
- 1999-03-02 AR ARP990100880A patent/AR018139A1/es unknown
- 1999-03-03 MY MYPI99000772A patent/MY123908A/en unknown
-
2000
- 2000-08-04 IS IS5582A patent/IS5582A/is unknown
- 2000-08-30 NO NO20004316A patent/NO315703B1/no not_active IP Right Cessation
- 2000-09-01 BG BG104740A patent/BG104740A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK13002000A3 (sk) | 2001-07-10 |
| EA200000804A1 (ru) | 2001-04-23 |
| CN1214011C (zh) | 2005-08-10 |
| YU52000A (sh) | 2003-02-28 |
| MY123908A (en) | 2006-06-30 |
| HRP20000574A2 (en) | 2001-08-31 |
| CN1291978A (zh) | 2001-04-18 |
| NZ506598A (en) | 2003-07-25 |
| NO20004316L (no) | 2000-11-06 |
| CA2322207A1 (en) | 1999-09-10 |
| GEP20033118B (en) | 2003-11-25 |
| IL137653A0 (en) | 2001-10-31 |
| TR200002542T2 (tr) | 2001-05-21 |
| OA11530A (en) | 2004-05-17 |
| JP2002505323A (ja) | 2002-02-19 |
| AP1244A (en) | 2004-02-04 |
| NO315703B1 (no) | 2003-10-13 |
| IS5582A (is) | 2000-08-04 |
| AU3294799A (en) | 1999-09-20 |
| ID25591A (id) | 2000-10-19 |
| EE200000506A (et) | 2002-04-15 |
| NO20004316D0 (no) | 2000-08-30 |
| AU753230B2 (en) | 2002-10-10 |
| HUP0100865A3 (en) | 2001-11-28 |
| PL342726A1 (en) | 2001-07-02 |
| UA71906C2 (en) | 2005-01-17 |
| KR20010041584A (ko) | 2001-05-25 |
| WO1999044994A1 (en) | 1999-09-10 |
| ZA994406B (en) | 2000-02-11 |
| HUP0100865A2 (hu) | 2001-08-28 |
| EP1060164A1 (en) | 2000-12-20 |
| BG104740A (en) | 2001-02-28 |
| BR9908470A (pt) | 2000-12-05 |
| AP2000001893A0 (en) | 2000-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR018139A1 (es) | Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento. | |
| ECSP034732A (es) | Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias | |
| PA8547701A1 (es) | Nucleosidos 4 substituidos. | |
| BR0111263A (pt) | Derivados de 2-aminocarbonil-9h-purina | |
| DE60330910D1 (de) | Verbindungen mit selektiverinhibierender wirkung für gsk3 | |
| AR026173A1 (es) | Inhibidores de neuraminidasas. | |
| ES2058527T3 (es) | Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen. | |
| BR9908545A (pt) | Derivado de piperidina, processo para a preparação do mesmo, composto, processo para a preparação do mesmo, e, composição farmacêutica | |
| AR029403A1 (es) | Derivados n-sustituidos de carbamoiloxialquil-azolio,un proceso para su fabricacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento | |
| BRPI0406717A (pt) | Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção | |
| ES2083359T3 (es) | Piperidinas 1,4-substituidas como inhibidores de la acetilcolinesterasa y su utilizacion en el tratamiento de la enfermedad de alzheimer. | |
| AR035792A1 (es) | Compuestos de n-(4-quinazolinil)-n-(1h-indazol-5-il) amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y metodo para prepararlo | |
| BR0113234A (pt) | Polimorfos de um análogo de epotilona | |
| UY26872A1 (es) | Derivados de la 4- fenil piridina | |
| ECSP034744A (es) | Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos | |
| AR008377A1 (es) | Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto | |
| ATE406893T1 (de) | Pharmazeutische zusammensetzung (kit) enthaltend dihydropyridinonverbindungen und eine verbindung mit immunmodulatorischer (oder antiinflammatorischer) wirkung und ihre verwendung | |
| ES2158778B1 (es) | Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen. | |
| BR0214243A (pt) | Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida | |
| AR004961A1 (es) | Modificacion cristalina v del clorhidrato de(r)-(-)-2-{n-[4-(1,1-dioxido-3- oxo-2,3-dihidro-benzisotiazol-2-il)-butil]-aminometil)cromano, unprocedimiento para su preparacion, medicamentos que lo contienen, el uso de dicho clorhidrato para la preparacion de medicamentos, una composicion para el | |
| UY27700A1 (es) | Compuestos oxo - azabiclícos. | |
| BR0309498A (pt) | Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças que são relacionadas com o ras, e, uso de compostos | |
| UY27548A1 (es) | Sales de ácido succínico de 5,7,14-triazatetraciclo (10.3.1.02.11.04,9) exadeca-2 (11),3,5,7,9-pentaeno y composiciones farmacéuticas | |
| AR013079A1 (es) | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios | |
| AR003966A1 (es) | Un derivado de difenilmetilenpiperidina, composición farmacéutica que lo contiene, metodo de preparación de dicho derivado y uso de este ultimo para preparar un medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |